Skip to content

Spyre Therapeutics, Inc. SYRE Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$179.44M+14.1%-$155.2M+25.4%-$148.97M+30.7%-$206.81M-11.2%-$208.93M+42.6%
$41.56M+4.2%$37.61M-16.1%$37.02M-30.0%$40.55M-9.1%$39.88M+5.5%
-$185.63M-9.3%-$169.25M-7.5%-$161.87M-7.0%-$154.18M+1.4%-$169.86M-53.3%
-$86.83M-$143.48M-$66.61M
$321.16M+34.4%$309.03M-24.8%$221.81M-36.4%$239.24M-28.8%$238.87M-56.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Spyre Therapeutics, Inc. generate?
Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
Where does Spyre Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.